What are the key biological and clinical characteristics of patients with ultra-low-risk MM?

During the 25th Congress of the European Hematology Association (EHA), the MM Hub spoke to Mehmet Samur, Dana-Farber Cancer Institute, Boston, US. We asked, What are the key biological and clinical characteristics of patients with ultra-low-risk MM?

Until now, the primary focus of genomic studies in the MM setting has been high-risk disease. Here, Mehmet Samur discusses a study in which patients with newly diagnosed MM underwent whole genome sequencing with the aim to define low-risk patients.